27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- BridgeBio Pharma Inc (NASDAQ:BBIO) is reportedly attracting takeover interest as some large pharmaceutical companies are studying a potential acquisition of the biotech firm.
- Deliberations are ongoing, and there’s no certainty they will result in a transaction, Bloomberg reported citing people familiar with the matter.
- BridgeBio may decide to remain independent longer so it can benefit from the results of upcoming drug trials, some of the people said.
- Most recently, BridgeBio Pharma announced results from the PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the fibroblast growth factor receptor.
- At the highest dose level evaluated to date (Cohort 5, 0.25 mg/kg once daily), the mean increase from baseline in annualized height velocity (AHV) for the ten children with six-month visits was +3.03 cm/yr.
- Soon after, the company raised $150 million via equity.
- The company aspires to generate $2 billion in annualized run-rate revenue within five years, Kumar said at the JPMorgan conference in January.
- Price Action: BBIO shares are up 0.67% at $15.00 during the premarket session on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!